BioVie completes patient enrolment in phase 2 trial of NE3107s pro-motoric activity in Parkinsons disease
By, Admin1 min read
Share
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced that the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
